Investor Presentaiton

Investor presentation Full year 2018 Slide 94 Biopharm R&D efforts reflect Novo Nordisk's commitment to satisfy unmet patient needs Aim to develop subcutaneous haemophilia products and long-acting growth hormone Novo Nordisk Biopharm portfolio Pursue leadership in HAEMOPHILIA Pursue subcutaneous bypassing and mimicking agents Research/ preclinical Haemophilia Growth hormone Phase 2 concizumab¹ Strengthen leadership in GROWTH DISORDERS Bring long-acting growth hormone somapacitan to market and expand indications Phase 3 N8-GP IV submitted somapacitan GHD and SGA² somapacitan AGHD submitted Pursue bolt-on opportunities Identify bolt-on acquisition or in-licensing opportunities in adjacent disease area Approved/ Launched NovoEight® Refixia® NovoThirteenⓇ NorditropinⓇ NovoSevenⓇ changing diabetes 1 Concizumab has completed phase 2 trials and is phase 3 ready; 2 Somapacitan GHD and SGA have completed phase 2 trials and are phase 3 ready Note: NovoThirteenⓇ and Refixia® are the brand names in the majority of countries, whereas these products are marketed as TRETTENⓇ and RebinynⓇ respectively in the USA IV: Intravenous; GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency; SGA: small for gestational age

View entire presentation